Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2020 | E2112: endocrine therapy plus entinostat in HR+ advanced breast cancer

Roisin Connolly, MD, University College Cork, Cork, Ireland, discusses the results of the E2112 study, a randomized, Phase III registration trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive, advanced breast cancer. Overall survival results and progression-free survival results did not indicate a benefit of the investigational arm of the standard endocrine therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.